Dr. Reddy's, Sun Pharma Apply for Generic Semaglutide in Canada

Indian Companies Enter Canadian Market

Both companies have already launched generic semaglutide products in India, where Ozempic patent protections expired earlier this year. Dr. Reddy's markets its version under the brand name Zyglutide, while Sun Pharma offers Semazen.

The applications add to the growing list of companies seeking Health Canada approval for generic versions of semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic medications.

Current Review Status

Health Canada has not yet approved either application, according to regulatory filings. The agency is currently reviewing nine generic semaglutide applications from various manufacturers, with decisions expected throughout 2026.

The standard Health Canada review timeline for generic drug applications is 180 days, though complex submissions may require additional time for assessment.

Global Generic Launch Strategy

Both Dr. Reddy's and Sun Pharma have established manufacturing capabilities for semaglutide injection products. In India, generic versions are priced significantly below branded alternatives, with monthly costs as low as $14 CAD equivalent.

The companies join other international manufacturers pursuing Canadian market entry, including:

• Aspen Pharmacare from South Africa
• Teva Pharmaceuticals
• Sandoz Canada
• Vimy Pharma, targeting domestic production

Regulatory Requirements

Generic manufacturers must demonstrate bioequivalence to reference products through clinical studies. Health Canada requires comprehensive quality data, manufacturing information, and stability testing results before granting market authorization.

All approved generic semaglutide products will be listed on Health Canada's Drug Product Database with pricing information available through the insurance coverage checker.

Market Access Timeline

Even with Health Canada approval, generic semaglutide availability depends on manufacturing scale-up and supply chain establishment. Industry experts anticipate initial Canadian market launches in the second half of 2026.

Provincial drug formularies will separately evaluate generic products for public insurance coverage, potentially reducing patient costs significantly compared to current branded pricing.

Competitive Landscape

The entry of established Indian pharmaceutical companies intensifies competition in the Canadian generic semaglutide market. Dr. Reddy's and Sun Pharma bring extensive regulatory experience and global distribution capabilities.

Current branded semaglutide products available in Canada include Mounjaro from Eli Lilly and Novo Nordisk's multiple formulations. Additional information about generic development is available in our FAQ section.